BofA notes that Eli Lilly’s (LLY) press release about its GLP-1 pricing deal with the federal government describes price concessions as “less onerous than what was just discussed at the White House press conference.” The firm, which contends that the pricing deal was “probably a good tradeoff overall,” makes no changes to its forecasts at this time and maintains a Buy rating and $950 price target on Eli Lilly shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- GLP-1 price cuts limit Hims advantage, says Needham
- Eli Lilly confirms weight loss drug agreement with U.S. government
- FDA awards second batch of National Priority Vouchers
- TrumpRx GLP-1 pricing ‘less bad than feared’ for Hims & Hers, says Citi
- Eli Lilly’s Stock (LLY) Falls After Trump Announces Deal to Lower Weight-Loss Drug Prices